Immuneering Corporation announced the granting of a U.S. composition of matter patent for its cancer drug, atebimetinib, in July. This patent is expected to provide exclusivity until 2042, with potential for patent term extension. Atebimetinib, a deep cyclic inhibitor administered as a once-daily pill, aims to offer longer-lasting benefits by overcoming resistance mechanisms in cancer treatment. Additional patent applications for atebimetinib are currently pending, with expiration anticipated into 2044.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511904-en) on August 13, 2025, and is solely responsible for the information contained therein.